Balsm Alofoq Medical Company vs Stryker Corporation
A head-to-head of Balsm Alofoq Medical Company (9620) and Stryker Corporation (SYK) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | 9620 | SYK |
|---|---|---|
| Market Cap | 56.25M SAR | $122.63B |
| P/E (TTM) | 29.75 | 37.02 |
| Forward P/E | — | 19.13 |
| P/S | 2.76 | 4.75 |
| P/B | 1.90 | 5.34 |
| EV/EBITDA | 13.70 | 18.77 |
| Dividend Yield | — | 1.06% |
| Profit Margin | 9.65% | 13.21% |
| Gross Margin | 38.24% | 63.96% |
| Operating Margin | 13.05% | 20.14% |
| Revenue Growth (YoY) | +3.00% | +2.63% |
| FCF Yield | — | 3.81% |
| Debt / Equity | 4.90 | 64.07 |
| Current Ratio | 10.26 | 2.11 |
Which is better: Balsm Alofoq Medical Company or Stryker Corporation?
- ✓Larger by market cap: Stryker Corporation
- ✓Cheaper valuation (lower P/E): Balsm Alofoq Medical Company
- ✓More profitable (net margin): Stryker Corporation
- ✓Faster revenue growth: Balsm Alofoq Medical Company
Across 10 available metrics, Balsm Alofoq Medical Company leads 7–3.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.